Clinical Trial Update: An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety study update on apalutamide plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in chemotherapy-naive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Zytiga) (abiraterone acetate)
• Apalutamide (Erleada) (apalutamide)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostatic Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-08-16